Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + radiotherapy + durvalumab
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
capecitabine + radiotherapy + durvalumab is a neoadjuvant treatment regimen being investigated for the treatment of locally advanced, operable stage II-III rectal cancer. This therapeutic sequence, evaluated in the Phase II PANDORA trial (NCT04083365) sponsored by AUSL Romagna Rimini, involves a standard five-week course of capecitabine-based chemoradiotherapy (825 mg/m² capecitabine twice daily with 5040 cGy radiotherapy) followed by consolidation immunotherapy with durvalumab (1500 mg every four weeks for three doses). Durvalumab is a human monoclonal antibody that targets programmed death-ligand 1 (PD-L1), preventing its interaction with PD-1 and CD80 to restore anti-tumor T-cell activity. Capecitabine acts as a radiosensitizer and cytotoxic agent by inhibiting thymidylate synthase, while radiotherapy induces direct DNA damage. The regimen aims to increase the pathological complete response (pCR) rate prior to surgical resection.
- Brand names
- ImfinziXeloda
- Other names
- PANDORA trial regimenradiotherapy-AUSL Romagna Rimini-rectal cancer
02
Targets
TS (Thymidylate synthase)CD274 (Programmed cell death protein 1 ligand 1)DNA
Beyond the preview
Go deeper on capecitabine + radiotherapy + durvalumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + radiotherapy + durvalumab.